The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

NPM-ALK(+) T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK(+) ALCL is CHOP polychemotherapy. Although patients initially respond favorably to CHOP, resistance, relapse, and death frequently occur. Recently, selective targeting of ALK has em...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: George, Suraj Konnath, Vishwamitra, Deeksha, Manshouri, Roxsan, Shi, Ping, Amin, Hesham M.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4170597/
https://ncbi.nlm.nih.gov/pubmed/25026277
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki